Biology of Blood and Marrow Transplantation
Volume 14, Issue 1 , Pages 10-15 , January 2008

Alemtuzumab for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease

  • David Gómez-Almaguer

      Affiliations

    • Servicio de Hematología, Hospital Universitario “Dr. José E. González,” Universidad Autónoma Nuevo León, Monterrey, NL, México
    • Corresponding Author InformationCorrespondence and reprint requests: David Gómez-Almaguer, MD, Hematology Department, University Hospital, UANL, Av. Madero y Gonzalitos s/n, Col. Mitras Centro CP 64460, Monterrey, NL, México.
    • ,
  • Guillermo J. Ruiz-Argüelles

      Affiliations

    • Centro de Hematología y Medicina Interna de Puebla, Puebla, México
    • ,
  • Luz del Carmen Tarín-Arzaga

      Affiliations

    • Servicio de Hematología, Hospital Universitario “Dr. José E. González,” Universidad Autónoma Nuevo León, Monterrey, NL, México
    • ,
  • Oscar González-Llano

      Affiliations

    • Servicio de Hematología, Hospital Universitario “Dr. José E. González,” Universidad Autónoma Nuevo León, Monterrey, NL, México
    • ,
  • Homero Gutiérrez-Aguirre

      Affiliations

    • Servicio de Hematología, Hospital Universitario “Dr. José E. González,” Universidad Autónoma Nuevo León, Monterrey, NL, México
    • ,
  • Olga Cantú-Rodríguez

      Affiliations

    • Servicio de Hematología, Hospital Universitario “Dr. José E. González,” Universidad Autónoma Nuevo León, Monterrey, NL, México
    • ,
  • José Jaime-Pérez

      Affiliations

    • Servicio de Hematología, Hospital Universitario “Dr. José E. González,” Universidad Autónoma Nuevo León, Monterrey, NL, México
    • ,
  • Antonio Carrasco-Yalán

      Affiliations

    • Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru
    • ,
  • Sergio Giralt

      Affiliations

    • M.D. Anderson Cancer Center, Houston, Texas

Received 23 August 2007 ,Accepted 16 October 2007.

References 

  1. Ferrara JL, Reddy P. Pathophysiology of graft-versus-host disease. Semin Hematol. 2006;43:3–10
  2. Martin PJ, Schoch G, Fisher L, et al. A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. Blood. 1990;76:1464–1472
  3. Nash RA, Antin JH, Karanes C, et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood. 2000;96:2062–2068
  4. Ratanatharathorn V, Nash RA, Przepiorka D, et al. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood. 1998;92:2303–2314
  5. Deeg HJ. How I treat refractory acute GVHD. Blood. 2007;109:4119–4126
  6. Van Lint MT, Milone G, Leotta S, et al. Treatment of acute graft-versus-host disease with prednisolone: significant survival advantage for day +5 responders and no advantage for nonresponders receiving anti-thymocyte globulin. Blood. 2006;107:4177–4181
  7. Antin JH, Chen AR, Couriel DR, Ho VT, Nash RA, Weisdorf D. Novel approaches to the therapy of steroid-resistant acute graft-versus-host disease. Biol Blood Marrow Transplant. 2004;10:655–668
  8. Basara N, Blau WI, Romer E, et al. Mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant patients. Bone Marrow Transplant. 1998;22:61–65
  9. Bolanos-Meade J, Jacobsohn DA, Margolis J, et al. Pentostatin in steroid-refractory acute graft-versus-host disease. J Clin Oncol. 2005;23:2661–2668
  10. Bruner RJ, Farag SS. Monoclonal antibodies for the prevention and treatment of graft-versus-host disease. Semin Oncol. 2003;30:509–519
  11. MacMillan ML, Weisdorf DJ, Davies SM, et al. Early antithymocyte globulin therapy improves survival in patients with steroid-resistant acute graft-versus-host disease. Biol Blood Marrow Transplant. 2002;8:40–46
  12. Patriarca F, Sperotto A, Damiani D, et al. Infliximab treatment for steroid-refractory acute graft-versus-host disease. Haematologica. 2004;89:1352–1359
  13. Przepiorka D, Kernan NA, Ippoliti C, et al. Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood. 2000;95:83–89
  14. Van Lint MT, Uderzo C, Locasciulli A, et al. Early treatment of acute graft-versus-host disease with high- or low-dose 6-methylprednisolone: a multicenter randomized trial from the Italian Group for Bone Marrow Transplantation. Blood. 1998;92:2288–2293
  15. Campath (alemtuzumab) prescribing information. Available at: http://berlexbayerhealthcare.com/html/products/pi/Campath_PI.pdf (accessed 2007).
  16. Buggins AG, Mufti GJ, Salisbury J, et al. Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with alemtuzumab. Blood. 2002;100:1715–1720
  17. Ginaldi L, De MM, Matutes E, et al. Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H. Leuk Res. 1998;22:185–191
  18. Hale G. The CD52 antigen and development of the CAMPATH antibodies. Cytotherapy. 2001;3:137–143
  19. Ratzinger G, Reagan JL, Heller G, Busam KJ, Young JW. Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation. Blood. 2003;101:1422–1429
  20. Ravandi F, O'Brien S. Alemtuzumab. Expert Rev Anticancer Ther. 2005;5:39–51
  21. Hale G, Bright S, Chumbley G, et al. Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement. Blood. 1983;62:873–882
  22. Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood. 2002;99:3554–3561
  23. Delgado J, Thomson K, Russell N, et al. Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation Study. Blood. 2006;107:1724–1730
  24. Khouri IF, Albitar M, Saliba RM, et al. Low-dose alemtuzumab (Campath) in myeloablative allogeneic stem cell transplantation for CD52-positive malignancies: decreased incidence of acute graft-versus-host-disease with unique pharmacokinetics. Bone Marrow Transplant. 2004;33:833–837
  25. Kottaridis PD, Milligan DW, Chopra R, et al. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood. 2000;96:2419–2425
  26. Morris E, Mackinnon S. Outcome following alemtuzumab (CAMPATH-1H)-containing reduced intensity allogeneic transplant regimen for relapsed and refractory non-Hodgkin's lymphoma (NHL). Transfus Apher Sci. 2005;32:73–83
  27. Perez-Simon JA, Kottaridis PD, Martino R, et al. Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders. Blood. 2002;100:3121–3127
  28. Busca A, Locatelli F, Lovisone E, et al. Treatment of severe refractory acute graft-versus-host disease of the gastrointestinal tract with Campath-1H. Biol Blood Marrow Transplant. 2005;11:734–736
  29. Carella AM, Beltrami G, Scalzulli PR, Carella AM, Corsetti MT. Alemtuzumab can successfully treat steroid-refractory acute graft-versus-host disease (aGVHD). Bone Marrow Transplant. 2004;33:131–132
  30. Wandroo F, Auguston B, Cook M, Craddock C, Mahendra P. Successful use of Campath-1H in the treatment of steroid refractory liver GvHD. Bone Marrow Transplant. 2004;34:285–287
  31. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15:825–828
  32. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11:945–956
  33. Gomez-Almaguer D, Ruiz-Arguelles GJ, Tarin-Arzaga LC, et al. Reduced-intensity stem cell transplantation in children and adolescents: the Mexican experience. Biol Blood Marrow Transplant. 2003;9:157–161
  34. Ruiz-Arguelles GJ, Gomez-Almaguer D, Ruiz-Arguelles A, Gonzalez-Llano O, Cantu OG, Jaime-Perez JC. Results of an outpatient-based stem cell allotransplant program using nonmyeloablative conditioning regimens. Am J Hematol. 2001;66:241–244
  35. Ruiz-Arguelles GJ, Gomez-Almaguer D, Morales-Toquero A, et al. The early referral for reduced-intensity stem cell transplantation in patients with Ph1 (+) chronic myelogenous leukemia in chronic phase in the imatinib era: results of the Latin American Cooperative Oncohematology Group (LACOHG) prospective, multicenter study. Bone Marrow Transplant. 2005;36:1043–1047
  36. Bordigoni P, Dimicoli S, Clement L, et al. Daclizumab, an efficient treatment for steroid-refractory acute graft-versus-host disease. Br J Haematol. 2006;135:382–385
  37. Busca A, Locatelli F, Marmont F, Ceretto C, Falda M. Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. Am J Hematol. 2007;82:45–52
  38. Carpenter PA, Lowder J, Johnston L, et al. A phase II multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant. 2005;11:465–471
  39. Ho VT, Zahrieh D, Hochberg E, et al. Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood. 2004;104:1224–1226
  40. Krejci M, Doubek M, Buchler T, Brychtova Y, Vorlicek J, Mayer J. Mycophenolate mofetil for the treatment of acute and chronic steroid-refractory graft-versus-host disease. Ann Hematol. 2005;84:681–685
  41. MacMillan ML, Couriel D, Weisdorf DJ, et al. A phase 2/3 multicenter randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host disease. Blood. 2007;109:2657–2662
  42. Schmidt-Hieber M, Fietz T, Knauf W, et al. Efficacy of the interleukin-2 receptor antagonist basiliximab in steroid-refractory acute graft-versus-host disease. Br J Haematol. 2005;130:568–574

PII: S1083-8791(07)00510-1

doi: 10.1016/j.bbmt.2007.08.052

Biology of Blood and Marrow Transplantation
Volume 14, Issue 1 , Pages 10-15 , January 2008

Article Tools

* Image Usage & Resolution